IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development. We are proud of this achievement and look forward to additional submissions going forward as we execute our strategy." The development of ANDA products has successfully been integrated into the Company's ongoing contract services business.
“This is a significant step forward in validating IGI's commitment to pharmaceutical product development. We are proud of this achievement and look forward to additional submissions going forward as we execute our strategy.”
Early RSV vaccination in pregnancy provides best protection for newborns